About: ABT-510     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:Medicine103740161, within Data Space : dbpedia.org associated with source document(s)
QRcode icon
http://dbpedia.org/describe/?url=http%3A%2F%2Fdbpedia.org%2Fresource%2FABT-510

ABT-510 is a molecular therapeutic drug that was the subject of research as a potential treatment for cancer. According to the Journal of Clinical Oncology, ABT-510 is a "subcutaneously (SC) administered nonapeptide thrombospondin analogue."

AttributesValues
rdf:type
rdfs:label
  • ABT-510
  • ABT-510
rdfs:comment
  • ABT-510 is a molecular therapeutic drug that was the subject of research as a potential treatment for cancer. According to the Journal of Clinical Oncology, ABT-510 is a "subcutaneously (SC) administered nonapeptide thrombospondin analogue."
  • ABT-510 est une molécule thérapeutique qui a été l'objet de recherche en tant que traitement potentiel contre le cancer. Selon le Journal of Clinical Oncology, ABT-510 est un "subcutaneously (SC) administered nonapeptide thrombospondin analogue."
foaf:isPrimaryTopicOf
dct:subject
Wikipage page ID
Wikipage revision ID
Link from a Wikipage to another Wikipage
sameAs
dbp:wikiPageUsesTemplate
has abstract
  • ABT-510 est une molécule thérapeutique qui a été l'objet de recherche en tant que traitement potentiel contre le cancer. Selon le Journal of Clinical Oncology, ABT-510 est un "subcutaneously (SC) administered nonapeptide thrombospondin analogue." Après une phase I d'essais cliniques peu concluante, une phase II a vu le jour en 2007 pour l'étude de ABT-510 pour le traitement de cancer métastatique. le traitement du mélanome a échoué à atteindre son principal point de terminaison entraînant l'arrêt de l'étude. Seulement trois des vingt-et-un patients ont atteint le critère principal de survie sans progression à 18 semaines, mais ces trois patients sont restés sans progression de 21, 34 et 42 semaines. Cependant, les données de biomarqueurs recueillies au cours de cette étude ont montré une diminution de la VEGF-C, des cellules endothéliales circulantes, des CD146 et des CD34/133, et que la dose maximale tolérée n'a pas encore été établie. l'étude pourrait envisager une dose plus élevée et/ou une combinaison de traitement.
  • ABT-510 is a molecular therapeutic drug that was the subject of research as a potential treatment for cancer. According to the Journal of Clinical Oncology, ABT-510 is a "subcutaneously (SC) administered nonapeptide thrombospondin analogue." Following inconclusive phase I clinical trials, a 2007 phase II study of ABT-510 for treatment of metastatic melanoma failed to reach its primary endpoint resulting in termination of the study. Only three out of twenty-one patients reached the primary endpoint of progression-free survival at 18 weeks, but these three patients remained progression-free for 21, 34, and 42 weeks. However, biomarker data collected during this study showed a decrease in VEGF-C, circulating endothelial cells, and CD146 and CD34/133 counts, and a maximum tolerated dose has still not been established. Further study could consider a higher dose and/or combination treatment.
prov:wasDerivedFrom
page length (characters) of wiki page
is foaf:primaryTopic of
is Link from a Wikipage to another Wikipage of
is Wikipage redirect of
Faceted Search & Find service v1.17_git51 as of Sep 16 2020


Alternative Linked Data Documents: PivotViewer | iSPARQL | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 08.03.3321 as of Jun 2 2021, on Linux (x86_64-generic-linux-glibc25), Single-Server Edition (61 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2021 OpenLink Software